nach oben

CNS Drugs

Erschienen in:

01.06.2012 | Leading Article

Antioxidants as Antidepressants

Fact or Fiction?

verfasst von: Dr Giovanni Scapagnini, Sergio Davinelli, Filippo Drago, Antonino De Lorenzo, Giovannangelo Oriani

Erschienen in: CNS Drugs | Ausgabe 6/2012

Einloggen, um Zugang zu erhalten

Abstract

Depression is a medical condition with a complex biological pattern of aetiology, involving genetic and epigenetic factors, along with different environmental stressors. Recent evidence suggests that oxidative stress pro-cesses might play a relevant role in the pathogenic mechanism(s) underlying many major psychiatric disorders, including depression.

Reactive oxygen and nitrogen species have been shown to modulate levels and activity of noradrenaline (norepinephrine), serotonin, dopamine and glutamate, the principal neurotransmitters involved in the neurobiology of depression. Major depression has been associated with lowered concentrations of several endogenous antioxidant compounds, such as vitamin E, zinc and coenzyme Q10, or enzymes, such as glutathione peroxidase, and with an impairment of the total antioxidant status. These observations introduce new potential targets for the development of therapeutic interventions based on antioxidant compounds.

The present review focuses on the possible role of oxidative stress processes in the pathogenesis of depression. The therapeutic potential of antioxidant compounds as a co-adjuvant treatment to conventional antidepressants is discussed. For instance, N-acetyl-cysteine has been shown to have a signif-icant benefit on depressive symptoms in a randomized placebo-controlled trial. Additionally, curcumin, the yellow pigment of curry, has been shown to strongly interfere with neuronal redox homeostasis in the CNS and to possess antidepressant activity in various animal models of depression, also thanks to its ability to inhibit monoamine oxidases. There is an urgent need to develop better tolerated and more effective treatments for depressive disorders and several antioxidant treatments appear promising and deserve further study.

Murray C, Lopez A. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet 1997; 349(9064): 1498–504PubMedCrossRef

Maes M, Leonard B, Fernandez A, et al. (Neuro)in-flammation and neuroprogression as new pathways and drug targets in depression: from antioxidants to kinase inhibitors. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35(3): 659–63PubMedCrossRef

Kulkarni S, Dhir A, Akula KK. Potentials of curcumin as an antidepressant. Scientific World J 2009; 9: 1233–41CrossRef

Coppen A. The biochemistry of affective disorders. Br J Psychiatry 1967; 113(504): 1237–64PubMedCrossRef

Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 1965; 122(5): 509–22PubMed

Owens MJ. Selectivity of antidepressants: from the monoamine hypothesis of depression to the SSRI revolution and beyond. J Clin Psychiatry 2004; 65 Suppl. 4: 5–10PubMed

Maes M, Bosmans E, Suy E, et al. Immune disturbances during major depression: upregulated expression of interleukin-2 receptors. Neuropsychobiology 1990–1991; 24(3): 115–20PubMedCrossRef

Stefansson H, Ophoff RA, Steinberg S, et al. Common variants conferring risk of schizophrenia. Nature 2009; 460(7256): 744–7PubMed

Maes M, Smith R, Scharpe S. The monocyte-T-lymphocyte hypothesis of major depression. Psychoneuroendocrinology 1995; 20(2): 111–6PubMedCrossRef

10.

Zorrilla EP, Luborsky L, McKay JR, et al. The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav Immun 2001; 15(3): 199–226PubMedCrossRef

11.

Dowlati Y, Herrmann N, Swardfager W, et al. A metaanalysis of cytokines in major depression. Biol Psychiatry 2010; 67(5): 446–57PubMedCrossRef

12.

Bower JE, Ganz PA, Aziz N, et al. Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosom Med 2002; 64(4): 604–11PubMed

13.

Meyers CA, Albitar M, Estey E. Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer 2005; 104(4): 788–93PubMedCrossRef

14.

Motivala SJ, Sarfatti A, Olmos L, et al. Inflammatory markers and sleep disturbance in major depression. Psychosom Med 2005; 67(2): 187–94PubMedCrossRef

15.

Sprague AH, Khalil RA. Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem Pharmacol 2009; 78(6): 539–52PubMedCrossRef

16.

Halliwell B. Biochemistry of oxidative stress. Biochem Soc Trans 2007; 35(Pt 5): 1147–50PubMed

17.

Edwards R, Peet M, Shay J, et al. Depletion of doco-sahexaenoic acid in red blood cell membranes of depressive patients. Biochem Soc Trans 1998; 26(2): S142PubMed

18.

Maes M, Christophe A, Delanghe J, et al. Lowered omega3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients. Psychiatry Res 1999; 85(3): 275–91PubMedCrossRef

19.

Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of aging. Nature 2000; 408(6809): 239–47PubMedCrossRef

20.

Bortolato M, Chen K, Shih JC. Monoamine oxidase in-activation: from pathophysiology to therapeutics. Adv Drug Deliv Rev 2008; 60(13–14): 1527–33PubMedCrossRef

21.

Gardner A, Pagani M, Wibom R, et al. Alterations of rCBF and mitochondrial dysfunction in major depressive disorder: a case report. Acta Psychiatr Scand 2003; 107(3): 233–9PubMedCrossRef

22.

Stockmeier CA, Mahajan GJ, Konick LC, et al. Cellular changes in the postmortem hippocampus in major depression. Biol Psychiatry 2004; 56(9): 640–50PubMedCrossRef

23.

Campbell S, MacQueen G. An update on regional brain volume differences associated with mood disorders. Curr Opin Psychiatry 2006; 19(1): 25–33PubMedCrossRef

24.

Zou K, Deng W, Li T, et al. Changes of brain morphometry in first-episode, drug-naïve, non-late-life adult patients with major depression: an optimized voxel-based morphometry study. Biol Psychiatry 2010; 67(2): 186–8PubMedCrossRef

25.

Baune BT, Miller R, McAfoose J, et al. The role of cognitive impairment in general functioning in major depression. Psychiatry Res 2010; 176(2–3): 183–9PubMedCrossRef

26.

Aznar S, Knudsen GM. Depression and Alzheimer’s disease: is stress the initiating factor in a common neuro-pathological cascade? J Alzheimers Dis 2011; 23(2): 177–93PubMed

27.

Hibbeln JR, Salem Jr N. Dietary polyunsaturated fatty acids and depression: when cholesterol does not satisfy. Am J Clin Nutr 1995; 62(1): 1–9PubMed

28.

Wolkowitz OM, Mellon SH, Epel ES, et al. Leukocyte telomere length in major depression: correlations with chronicity, inflammation and oxidative stress-preliminary findings. PLoS One 2011; 6(3): e17837PubMedCrossRef

29.

Eren I, Nazroglu M, Demirdas A, et al. Venlafaxine modulates depression-induced oxidative stress in brain and medulla of rat. Neurochem Res 2007; 32(3): 497–505PubMedCrossRef

30.

Bilici M, Efe H, Koroglu MA, et al. Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments. J Affective Disord 2001; 64(1): 43–51CrossRef

31.

Sarandol A, Sarandol E, Eker SS, et al. Major depressive disorder is accompanied with oxidative stress: short-term antidepressant treatment does not alter oxidative-antioxidative systems. Hum Psychopharmacol Clin Exp 2007; 22(2): 67–73CrossRef

32.

Khanzode SD, Dakhale GN, Khanzode SS, et al. Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors. Redox Rep 2003; 8(6): 365–70PubMedCrossRef

33.

Selley ML. Increased (E)-4-hydroxy-2-nonenal and asymmetric dimethylarginine concentrations and decreased nitric oxide concentrations in the plasma of patients with major depression. J Affect Disord. 2004; 80(2–3): 249–56PubMedCrossRef

34.

Britt SG, Chiu VW, Redpath GT, et al. Elimination of ascorbic acid-induced membrane lipid peroxidation and serotonin receptor loss by Trolox-C, a water soluble analogue of vitamin E. J Recept Res 1992; 12(2): 181–200PubMed

35.

Takuma Baba A, Matsuda T. Astrocyte apoptosis: implications for neuroprotection. Prog Neurobiol 2004; 72(2): 111–27CrossRef

36.

Mattson MP. Modification of ion homeostasis by lipid peroxidation: roles in neuronal degeneration and adaptive plasticity. Trends Neurosci 1998; 21(2): 53–7PubMedCrossRef

37.

Maes M, Mihaylova I, Kubera M, et al. IgM-mediated autoimmune responses directed against multiple neoepitopes in depression: new pathways that underpin the inflammatory and neuroprogressive pathophysiology. J Affect Disord 2011; 135(1–3): 414–8PubMedCrossRef

38.

Maes M, Ringel K, Kubera M, et al. Increased autoimmune activity against 5-HT: a key component of depression that is associated with inflammation and activation of cell-mediated immunity, and with severity and staging of depression. J Affect Disord. Epub 2011 Dec 12

39.

Szuster-Ciesielska A, Slotwińska M, Stachura A, et al. Accelerated apoptosis of blood leukocytes and oxidative stress in blood of patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32(3): 686–94PubMedCrossRef

40.

Herken H, Gurel A, Selek S, et al. Adenosine deaminase, nitric oxide, superoxide dismutase, and xanthine oxidase in patients with major depression: impact of antidepressant treatment. Arch Med Res 2007; 38(2): 247–52PubMedCrossRef

41.

Cumurcu BE, Ozyurt H, Etikan I, et al. Total antioxidant capacity and total oxidant status in patients with major depression: impact of antidepressant treatment. Psychiatry Clin Neurosci 2009; 63(5): 639–45PubMedCrossRef

42.

Clay HB, Sillivan S, Konradi C. Mitochondrial dysfunction and pathology in bipolar disorder and schizophrenia. Int J Dev Neurosci 2011; 29(3): 311–24PubMedCrossRef

43.

Fattal O, Budur K, Vaughan AJ, et al. Review of the literature on major mental disorders in adult patients with mitochondrial diseases. Psychosomatics 2006; 47(1): 1–7PubMedCrossRef

44.

Shao L, Martin MV, Watson SJ, et al. Mitochondrial involvement in psychiatric disorders. Ann Med 2008; 40(4): 281–95PubMedCrossRef

45.

Ben-Shachar D, Karry R. Neuroanatomical pattern of mitochondrial complex I pathology varies between schizophrenia, bipolar disorder and major depression. PLoS One 2008; 3(11):e3676PubMedCrossRef

46.

Andreazza AC, Kauer-Sant’anna M, Frey BN, et al. Oxidative stress markers in bipolar disorder: a meta-analysis. J Affect Disord 2008; 111(2–3): 135–44PubMedCrossRef

47.

Abdalla DS, Monteiro HP, Oliveira JA, et al. Activities of superoxide dismutase and glutathione peroxidase in schizophrenic and manic-depressive patients. Clin Chem 1986; 32(5): 805–7PubMed

48.

Kuloglu M, Ustundag B, Atmaca M, et al. Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct 2002; 20(2): 171–5PubMedCrossRef

49.

Andreazza AC, Frey BN, Erdtmann B, et al. DNA damage in bipolar disorder. Psychiatry Res 2007; 153(1): 27–32PubMedCrossRef

50.

Wang JF, Shao L, Sun X, et al. Increased oxidative stress in the anterior cingulate cortex of subjects with bipolar disorder and schizophrenia. Bipolar Disord 2009; 11(5): 523–9PubMedCrossRef

51.

Kato T, Kato N. Mitochondrial dysfunction in bipolar disorder. Bipolar Disord 2000; 2(3 Pt 1): 180–90PubMedCrossRef

52.

Andreazza AC, Kapczinski F, Kauer-Sant’Anna M, et al. 3-Nitrotyrosine and glutathione antioxidant system in patients in the early and late stages of bipolar disorder. J Psychiatry Neurosci 2009; 34(4): 263–71PubMed

53.

Iwamoto K, Bundo M, Kato T. Altered expression of mitochondria-related genes in postmortem brains of patients with bipolar disorder or schizophrenia, as revealed by large-scale DNA microarray analysis. Hum Mol Genet 2005; 14(2): 241–53PubMedCrossRef

54.

Huang J, Perlis RH, Lee PH, et al. Cross-disorder genome-wide analysis of schizophrenia, bipolar disorder, and depression. Am J Psychiatry 2010; 167(10): 1254–63PubMedCrossRef

55.

Gawryluk JW, Wang JF, Andreazza AC, et al. Decreased levels of glutathione, the major brain antioxidant, in postmortem prefrontal cortex from patients with psychiatric disorders. Int J Neuropsychopharmacol 2011; 14(1): 123–30PubMedCrossRef

56.

Gawryluk JW, Wang JF, Andreazza AC, et al. Prefrontal cortex glutathione S-transferase levels in patients with bipolar disorder, major depression and schizophrenia. Int J Neuropsychopharmacol 2011; 14(8): 1069–74PubMedCrossRef

57.

Kapczinski F, Frey BN, Andreazza AC, et al. Increased oxidative stress as a mechanism for decreased BDNF levels in acute manic episodes. Rev Bras Psiquiatr 2008; 30(3): 243–5PubMedCrossRef

58.

Kuloglu M, Atmaca M, Tezcan E, et al. Antioxidant enzyme activities and malondialdehyde levels in patients with obsessive-compulsive disorder. Neuropsychobiology 2002; 46(1): 27–32PubMedCrossRef

59.

Chakraborty S, Singh OP, Dasgupta A, et al. Correlation between lipid peroxidation-induced TBARS level and disease severity in obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33(2): 363–6PubMedCrossRef

60.

Ersan S, Bakir S, Erdal Ersan E, et al. Examination of free radical metabolism and antioxidant defence system elements in patients with obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30(6): 1039–42PubMedCrossRef

61.

Ozdemir E, Cetinkaya S, Ersan S, et al. Serum selenium and plasma malondialdehyde levels and antioxidant enzyme activities in patients with obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33(1): 62–5PubMedCrossRef

62.

Selek S, Herken H, Bulut M, et al. Oxidative imbalance in obsessive compulsive disorder patients: a total evaluation of oxidant-antioxidant status. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32(2): 487–91PubMedCrossRef

63.

Halliwell B, Whiteman M. Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean? Br J Pharmacol 2004; 142(2): 231–55PubMedCrossRef

64.

Litescu SC, Eremia S, Radu GL. Methods for the determination of antioxidant capacity in food and raw materials. Adv Exp Med Biol 2011; 698: 241–9CrossRef

65.

Pun PB, Gruber J, Tang SY, et al. Ageing in nematodes: do antioxidants extend lifespan in Caenorhabditis elegans? Biogerontology 2010; 11(1): 17–30PubMedCrossRef

66.

McLoughlin IJ, Hodge JS. Zinc in depressive disorder. Acta Psychiatr Scand 1990; 82: 451–3PubMedCrossRef

67.

Whittle N, Lubec G, Singewald N. Zinc deficiency induces enhanced depression-like behavior and altered limbic activation reversed by antidepressant treatment in mice. Amino Acids 2009; 36: 147–58PubMedCrossRef

68.

Takeda A, Tamano H, Ogawa T, et al. Significance of serum glucocorticoid and chelatable zinc in depression and cognition in zinc deficiency. Behav Brain Res. Epub 2011 Sep 19

69.

Rayman MP. The importance of selenium to human health. Lancet 2000; 356(9225): 233–41PubMedCrossRef

70.

Lai J, Moxey A, Nowak G, et al. The efficacy of zinc supplementation in depression: systematic review of randomised controlled trials. J Affect Disord Epub 2011 Jul 26

71.

Rice ME. Ascorbate regulation and its neuroprotective role in the brain. Trends Neurosci 2000; 23(5): 209–16PubMedCrossRef

72.

DeSantis J. Scurvy and psychiatric symptoms. Perspec Psychiatr Care 1993; 29(1): 18–22CrossRef

73.

Coochi P, Silenzi M, Calabri G, et al. Antidepressant effect of vitamin Pediatrics 1980; 65(4): 862–3

74.

Brody S. High-dose ascorbic acid increases intercourse frequency and improves mood: a randomized controlled clinical trial. Biol Psychiatry 2002; 52(4): 371–4PubMedCrossRef

75.

Brody S, Preut R, Schommer K, et al. A randomized controlled trial of high dose ascorbic acid for reduction of blood pressure, cortisol, and subjective responses to psychological stress. Psychopharmacology 2002; 159(3): 319–24PubMedCrossRef

76.

Binfaré RW, Rosa AO, Lobato KR, et al. Ascorbic acid administration produces an antidepressant-like effect: evidence for the involvement of monoaminergic neurotransmission. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33(3): 530–40PubMedCrossRef

77.

Tagliari B, Scherer EB, Machado FR, et al. Antioxidants prevent memory deficits provoked by chronic variable stress in rats. Neurochem Res. Epub 2011 Aug 7

78.

Lobato KR, Cardoso CC, Binfaré RW, et al. alpha-Tocopherol administration produces an antidepressantlike effect in predictive animal models of depression. Behav Brain Res 2010; 209(2): 249–59PubMedCrossRef

79.

Milaneschi Y, Bandinelli S, Penninx BW, et al. The relationship between plasma carotenoids and depressive symptoms in older persons. World J Biol Psychiatry. Epub 2011 Sep

80.

Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Measure 1977; 1(3): 385–401CrossRef

81.

Aruoma OI, Halliwell B, Hoey BM, et al. The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic Biol Med 1989; 6(6): 593–7PubMedCrossRef

82.

Holdiness MR. Clinical pharmokinetics of N-acetylcysteine. Clin Pharmacokinet 1991; 20(2): 123–34PubMedCrossRef

83.

Dean OM, van den Buuse M, Berk M, et al. N-acetyl cysteine restores brain glutathione loss in combined 2-cyclohexene-1-one and D-amphetamine-treated rats: relevance to schizophrenia and bipolar disorder. Neurosci Lett 2011; 499(3): 149–53PubMedCrossRef

84.

Fontaine MA, Geddes JW, Banks A, et al. Effect of exogenous and endogenous antioxidants on 3-nitropionic acid-induced in vivo oxidative stress and striatal lesions: insights into Huntington’s disease. J Neurochem 2000; 75(4): 1709–15PubMedCrossRef

85.

Robinson RA, Joshi G, Huang Q, et al. Proteomic analysis of brain proteins in APP/PS-1 human double mutant knock-in mice with increasing amyloid β-peptide deposition: insights into the effects of in vivo treatment with N-acetylcysteine as a potential therapeutic intervention in mild cognitive impairment and Alzheimer’s disease. Proteomics. Epub 2011 Aug 30

86.

Qian HR, Yang Y. Neuron differentiation and neuritogenesis stimulated by N-acetylcysteine (NAC). Acta Pharmacol Sin 2009; 30(7): 907–12PubMedCrossRef

87.

Janaky R, Dohovics R, Saransaari P, et al. Modulation of [3H]dopamine release by glutathione in mouse striatal slices. Neurochem Res 2007; 32(8): 1357–64PubMedCrossRef

88.

Khan M, Sekhon B, Jatana M, et al. Administration of N-acetylcysteine after focal cerebral ischemia protects brain and reduces inflammation in a rat model of experimental stroke. J Neurosci Res 2004; 76(4): 519–27PubMedCrossRef

89.

Ferreira FR, Biojone C, Joca SR, et al. Antidepressant-like effects of N-acetyl-L-cysteine in rats. Behav Pharmacol 2008; 19(7): 747–50PubMedCrossRef

90.

Berk M, Copolov D, Dean O, et al. N-acetyl cysteine as a glutathione precursor for schizophrenia: a double-blind, randomized, placebo-controlled trial. Biol Psychiatry 2008; 64(9): 361–8PubMedCrossRef

91.

Lafleur DL, Pittenger C, Kelmendi C, et al. N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessivecompulsive disorder. Psychopharmacology (Berl) 2006; 184(2): 254–6CrossRef

92.

Odlaug BL, Grant JE. N-acetyl cysteine in the treatment of grooming disorders. J Clin Psychopharmacol 2007; 27(2): 227–9PubMedCrossRef

93.

Grant JE, Kim SW, Odlaug BL. N-acetyl cysteine, a glutamatemodulating agent, in the treatment of pathological gambling: a pilot study. Biol Psychiatry 2007; 62(6): 652–7PubMedCrossRef

94.

Mardikian PN, LaRowe SD, Hedden S, et al. An openlabel trial of N-acetylcysteine for the treatment of cocaine dependence: a pilot study. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31(2): 389–94PubMedCrossRef

95.

Berk M, Copolov DL, Dean O, et al. N-acetyl cysteine for depressive symptoms in bipolar disorder: a double-blind randomized placebo-controlled trial. Biol Psychiatry 2008; 64(6): 468–75PubMedCrossRef

96.

Magalhães PV, Dean OM, Bush AI, et al. N-acetyl cysteine add-on treatment for bipolar II disorder: a subgroup analysis of a randomized placebo-controlled trial. J Affect Disord 2011; 129(1–3): 317–20PubMedCrossRef

97.

Berk M, Dean O, Cotton SM, et al. The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: an open label trial. J Affect Disord. Epub 2011 Jun 28

98.

Scapagnini G, Caruso C, Calabrese V. Therapeutic potential of dietary polyphenols against brain ageing and neurodegenerative disorders. Adv Exp Med Biol 2011; 698: 27–35CrossRef

99.

Scapagnini G, Vasto S, Abraham NG, et al. Modulation of Nrf2/ARE pathway by food polyphenols: a nutritional neuroprotective strategy for cognitive and neurodegenerative disorders. Mol Neurobiol 2011; 44(2): 192–201PubMedCrossRef

100.

Priyadarsini KI, Guha SN, Rao MN. Physicochemical properties and antioxidant activities of methoxy phenols. Free Radic Biol Med 1998; 24(6): 933–41PubMedCrossRef

101.

Sreejayan A, Rao MN. Nitric oxide scavenging by curcuminoids. J Pharm Pharmacol 1997; 49(1): 105–7PubMedCrossRef

102.

Masuda T, Hidaka K, Shinohara A, et al. Chemical studies on antioxidant mechanism of curcuminoid: analysis of radical reaction products from curcumin. J Agric Food Chem 1999; 47(1): 71–7PubMedCrossRef

103.

Jovanovic SV, Boone CW, Steenken S. How curcumin works preferentially with water soluble antioxidants. J Am Chem Soc 2001; 123(13): 3064–8PubMedCrossRef

104.

Huang MT, Newmark HL, Frenkel K. Inhibitory effects of curcumin on tumorigenesis in mice. J Cell Biochem Suppl 1997; 27: 26–34PubMedCrossRef

105.

Ramos-Gomez M, Kwak MK, Dolan PM, et al. Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription fac-tor-deficient mice. Proc Natl Acad Sci USA 2001; 98(6): 3410–5PubMedCrossRef

106.

Singh S, Aggarwal Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane). J Biol Chem 1995; 270(42): 24995–5000PubMedCrossRef

107.

Balogun E, Hoque M, Gong P, et al. Curcumin activates the haem oxygenase-1 gene via regulation of Nrf2 and the antioxidant-responsive element. Biochem J 2003; 371(Pt 3): 887–95PubMedCrossRef

108.

Kulkarni SK, Bhutani MK, Bishnoi M. Antidepressant activity of curcumin: involvement of serotonin and dopamine system. Psychopharmacology (Berl) 2008; 201(3): 435–42CrossRef

109.

Gupta A, Vij G, Sharma S, et al. Curcumin, a polyphenolic antioxidant, attenuates chronic fatigue syndrome in murine water immersion stress model. Immunobiology 2009; 214(1): 33–9PubMedCrossRef

110.

Xu Y, Ku B, Cui L, et al. Curcumin reverses impaired hippocampal neurogenesis and increases ser otonin receptor 1A mRNA and brain-derived neurotrophic factor expression in chronically stressed rats. Brain Res 2007; 1162:9–18PubMedCrossRef

111.

Xu Y, Ku B, Tie L, et al. Curcumin reverses the effects of chronic stress on behavior, the HPA axis, BDNF expression and phosphorylation of CREB. Brain Res 2006; 1122(1): 56–64PubMedCrossRef

112.

Bhutani MK, Bishnoi M, Kulkarni SK. Anti-depressant like effect of curcumin and its combination with piperine in unpredictable chronic stress-induced behavioral, biochemical and neurochemical changes. Pharmacol Biochem Behav 2009; 92(1): 39–43PubMedCrossRef

113.

Zeni AL, Zomkowski AD, Maraschin M. Ferulic acid exerts antidepressant-like effect in the tail suspension test in mice: evidence for the involvement of the serotonergic system. Eur J Pharmacol. Epub 2012 Jan 12

114.

Sachdeva AK, Kuhad A, Chopra K. Epigallocatechin gallate ameliorates behavioral and biochemical deficits in rat model of load-induced chronic fatigue syndrome. Brain Res Bull 2011; 86(3–4): 165–72PubMedCrossRef

115.

Zhu WL, Shi HS, Wei YM, et al. Green tea polyphenols produce antidepressant-like effects in adult mice. Pharmacol Res 2012; 65(1): 74–80PubMedCrossRef

116.

Rojas P, Serrano-García N, Medina-Campos ON, et al. Antidepressant-like effect of a Ginkgo biloba extract (EGb761) in the mouse forced swimming test: role of oxidative stress. Neurochem Int 2011; 59(5): 628–36PubMedCrossRef

Titel: Antioxidants as Antidepressants
Fact or Fiction?
verfasst von: Dr Giovanni Scapagnini
Sergio Davinelli
Filippo Drago
Antonino De Lorenzo
Giovannangelo Oriani
Publikationsdatum: 01.06.2012
Verlag: Springer International Publishing
Erschienen in: CNS Drugs / Ausgabe 6/2012
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI: https://doi.org/10.2165/11633190-000000000-00000

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

23.04.2024 | Parkinson-Krankheit | Podcast | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Antioxidants as Antidepressants

Fact or Fiction?

Abstract

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Hustenstiller lindert Agitation bei Alzheimer

Checkpointhemmer auch bei MS sicher

Update Neurologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2012

Pharmacogenetically Driven Treatments for Alcoholism

Adherence to Treatment with Selective Serotonin Reuptake Inhibitors and the Risk for Fractures and Bone Loss

Comparative Effectiveness of Atypical Antipsychotics in Schizophrenia

A Comprehensive Review of Rapid-Onset Opioids for Breakthrough Pain

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Hustenstiller lindert Agitation bei Alzheimer

Checkpointhemmer auch bei MS sicher

Update Neurologie